• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

吡非尼酮对树突状细胞和肺移植排斥反应的抑制作用。

Inhibitory effects of pirfenidone on dendritic cells and lung allograft rejection.

机构信息

Division of Respiratory Medicine, Department of Medicine, Children's Hospital Boston, Harvard Medical School, Boston, MA, USA.

出版信息

Transplantation. 2012 Jul 27;94(2):114-22. doi: 10.1097/TP.0b013e3182584879.

DOI:10.1097/TP.0b013e3182584879
PMID:22743547
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3402635/
Abstract

BACKGROUND

Pirfenidone (PFD) is an antifibrotic agent with beneficial effects on proinflammatory disorders. In this study, we further investigated PFD and long-acting form, "deuterated PFD," immune-modulating properties by evaluating their effects on mouse dendritic cells (DCs).

METHODS

The effects of PFD on DCs were examined in vivo using an orthotopic mouse lung transplant model and in vitro using isolated bone marrow-derived DCs in response to lipopolysaccharide and allogeneic stimulation.

RESULTS

In mouse lung transplants, PFD and deuterated PFD treatment improved allograft lung function based on peak airway pressure, less infiltrates/consolidation on micro-computed tomography scan imaging, and reduced lung rejection/injury. DC activation from lung allografts was suppressed with PFD, and there seemed to be a greater effect of PFD on CD11c(+)CD11b(-)CD103(+) lung DCs. In addition, PFD reduced the expression of several proinflammatory cytokines/chemokines from lung allografts. In vitro, DCs treated with PFD showed decreased expression of major histocompatibility complex class II and costimulatory molecules and the capacity of these DCs to stimulate T-cell activation was impaired, although antigen uptake was preserved. PFD directly inhibited the release of inflammatory cytokines from isolated DCs, was associated with a reduction of stress protein kinases, and attenuated lipopolysaccharide-dependent mitogen-activated protein kinase p38 phosphorylation.

CONCLUSIONS

PFD has lung allograft protective properties, and in addition to its known effects on T-cell biology, PFD immune-modulating activities encompass inhibitory effects on DC activation and function.

摘要

背景

吡非尼酮(PFD)是一种抗纤维化药物,对促炎疾病有有益作用。在这项研究中,我们通过评估其对小鼠树突状细胞(DC)的影响,进一步研究了 PFD 和长效形式“氘代 PFD”的免疫调节特性。

方法

使用原位小鼠肺移植模型和分离的骨髓源性 DC 对脂多糖和同种异体刺激的反应,在体内和体外研究 PFD 对 DC 的作用。

结果

在小鼠肺移植中,PFD 和氘代 PFD 治疗可改善同种异体肺功能(基于气道峰压)、减少微计算机断层扫描成像上的浸润/实变,并减少肺排斥/损伤。PFD 抑制了来自肺移植物的 DC 活化,并且 PFD 对 CD11c(+)CD11b(-)CD103(+)肺 DC 的作用似乎更大。此外,PFD 降低了来自肺移植物的几种促炎细胞因子/趋化因子的表达。在体外,用 PFD 处理的 DC 显示主要组织相容性复合物 II 和共刺激分子的表达降低,并且这些 DC 刺激 T 细胞活化的能力受损,尽管抗原摄取得到保留。PFD 直接抑制分离的 DC 释放炎症细胞因子,与应激蛋白激酶减少以及减弱脂多糖依赖性丝裂原激活蛋白激酶 p38 磷酸化有关。

结论

PFD 具有肺移植保护特性,除了对 T 细胞生物学的已知作用外,PFD 的免疫调节活性还包括抑制 DC 活化和功能。

相似文献

1
Inhibitory effects of pirfenidone on dendritic cells and lung allograft rejection.吡非尼酮对树突状细胞和肺移植排斥反应的抑制作用。
Transplantation. 2012 Jul 27;94(2):114-22. doi: 10.1097/TP.0b013e3182584879.
2
Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses.吡非尼酮可抑制T细胞活化、增殖、细胞因子和趋化因子的产生以及宿主同种异体反应。
Transplantation. 2009 Aug 15;88(3):330-8. doi: 10.1097/TP.0b013e3181ae3392.
3
Bone marrow-derived immature dendritic cells prime in vivo alloreactive T cells for interleukin-4-dependent rejection of major histocompatibility complex class II antigen-disparate cardiac allograft.骨髓来源的未成熟树突状细胞在体内使同种异体反应性T细胞致敏,以实现对主要组织相容性复合体II类抗原不相合心脏移植的白细胞介素-4依赖性排斥反应。
Transplantation. 2003 Feb 15;75(3):407-13. doi: 10.1097/01.TP.0000044172.19087.22.
4
Tolerogenic dendritic cells suppress murine corneal allograft rejection by modulating CD28/CTLA-4 expression on regulatory T cells.调节性 T 细胞表面 CD28/CTLA-4 的表达抑制耐受树突状细胞抑制小鼠角膜同种异体移植排斥反应。
Cell Biol Int. 2014 Jul;38(7):835-48. doi: 10.1002/cbin.10268. Epub 2014 Mar 14.
5
The cannabinoid receptor 2 is involved in acute rejection of cardiac allografts.大麻素受体2参与心脏同种异体移植的急性排斥反应。
Life Sci. 2015 Oct 1;138:29-34. doi: 10.1016/j.lfs.2015.02.012. Epub 2015 Mar 2.
6
Dryocrassin suppresses immunostimulatory function of dendritic cells and prolongs skin allograft survival.绵马贯众素抑制树突状细胞的免疫刺激功能并延长皮肤同种异体移植的存活时间。
Cell Transplant. 2014;23(4-5):641-56. doi: 10.3727/096368914X678373.
7
Inhibition of arterial allograft intimal hyperplasia using recipient dendritic cells pretreated with B7 antisense peptide.使用经B7反义肽预处理的受体树突状细胞抑制动脉同种异体移植物内膜增生
Clin Dev Immunol. 2012;2012:892687. doi: 10.1155/2012/892687. Epub 2012 Feb 6.
8
Dendritic cells with METTL3 gene knockdown exhibit immature properties and prolong allograft survival.敲低 METTL3 基因的树突状细胞表现出未成熟的特性,并延长移植物的存活时间。
Genes Immun. 2020 May;21(3):193-202. doi: 10.1038/s41435-020-0099-3. Epub 2020 May 27.
9
IL-17 promotes Type 1 T cell response through modulating dendritic cell function in acute allograft rejection.白细胞介素-17在急性同种异体移植排斥反应中通过调节树突状细胞功能促进1型T细胞反应。
Int Immunopharmacol. 2014 Jun;20(2):290-7. doi: 10.1016/j.intimp.2014.03.010. Epub 2014 Mar 25.
10
Inhibition of the purinergic pathway prolongs mouse lung allograft survival.嘌呤能途径的抑制可延长小鼠肺移植的存活时间。
Am J Respir Cell Mol Biol. 2014 Aug;51(2):300-10. doi: 10.1165/rcmb.2013-0362OC.

引用本文的文献

1
Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases.吡非尼酮和尼达尼布的上市后安全性问题:对来自美国食品药品监督管理局不良事件报告系统数据库和日本药品不良事件报告数据库的个体病例安全报告的分析
Front Pharmacol. 2025 Apr 28;16:1530697. doi: 10.3389/fphar.2025.1530697. eCollection 2025.
2
Add-on therapy for pulmonary fibrosis, a forthcoming era with implications for practice: the BI 101550 and RELIEF trials.用于肺纤维化的附加疗法:一个对临床实践有影响的崭新时代——BI 101550和RELIEF试验
Breathe (Sheff). 2023 Sep;19(3):230090. doi: 10.1183/20734735.0090-2023. Epub 2023 Sep 12.
3
Investigating the possible mechanisms of pirfenidone to be targeted as a promising anti-inflammatory, anti-fibrotic, anti-oxidant, anti-apoptotic, anti-tumor, and/or anti-SARS-CoV-2.研究吡非尼酮作为一种有前途的抗炎、抗纤维化、抗氧化、抗凋亡、抗肿瘤和/或抗 SARS-CoV-2 的可能机制。
Life Sci. 2022 Nov 15;309:121048. doi: 10.1016/j.lfs.2022.121048. Epub 2022 Oct 7.
4
Lung Fibrosis and Fibrosis in the Lungs: Is It All about Myofibroblasts?肺纤维化与肺部的纤维化:一切都与肌成纤维细胞有关吗?
Biomedicines. 2022 Jun 15;10(6):1423. doi: 10.3390/biomedicines10061423.
5
The Efficacy and Safety of Pirfenidone Combined With Immunosuppressant Therapy in Connective Tissue Disease-Associated Interstitial Lung Disease: A 24-Week Prospective Controlled Cohort Study.吡非尼酮联合免疫抑制疗法治疗结缔组织病相关性间质性肺病的疗效和安全性:一项为期24周的前瞻性对照队列研究。
Front Med (Lausanne). 2022 May 12;9:871861. doi: 10.3389/fmed.2022.871861. eCollection 2022.
6
Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond.吡非尼酮用于特发性肺纤维化及其他病症
Card Fail Rev. 2022 Apr 14;8:e12. doi: 10.15420/cfr.2021.30. eCollection 2022 Jan.
7
Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease.抗纤维化药物在特发性炎性肌病相关间质性肺疾病管理中的作用
Ther Adv Musculoskelet Dis. 2021 Dec 9;13:1759720X211060907. doi: 10.1177/1759720X211060907. eCollection 2021.
8
Antifibrotic drugs in lung transplantation and chronic lung allograft dysfunction: a review.肺移植和慢性肺移植物功能障碍中的抗纤维化药物:综述。
Eur Respir Rev. 2021 Jun 1;30(160). doi: 10.1183/16000617.0050-2021. Print 2021 Jun 30.
9
Regulatory Immune Cells in Idiopathic Pulmonary Fibrosis: Friends or Foes?特发性肺纤维化中的调节性免疫细胞:是敌是友?
Front Immunol. 2021 Apr 22;12:663203. doi: 10.3389/fimmu.2021.663203. eCollection 2021.
10
Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications.结缔组织病相关间质性肺病(CTD-ILD)中的抗纤维化药物:从机制洞察到治疗应用
Drugs Context. 2021 Jan 15;10. doi: 10.7573/dic.2020-8-6. eCollection 2021.

本文引用的文献

1
Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment.探索性分析吡非尼酮 III 期临床试验结果,发现特发性肺纤维化患者亚群从治疗中获益。
Respir Res. 2011 Oct 28;12(1):143. doi: 10.1186/1465-9921-12-143.
2
Regulation and functions of the IL-10 family of cytokines in inflammation and disease.白细胞介素-10 家族细胞因子在炎症和疾病中的调节和功能。
Annu Rev Immunol. 2011;29:71-109. doi: 10.1146/annurev-immunol-031210-101312.
3
Non-steroid agents for idiopathic pulmonary fibrosis.用于特发性肺纤维化的非甾体类药物。
Cochrane Database Syst Rev. 2010 Sep 8(9):CD003134. doi: 10.1002/14651858.CD003134.pub2.
4
Development and functional specialization of CD103+ dendritic cells.CD103+ 树突状细胞的发育与功能特化。
Immunol Rev. 2010 Mar;234(1):268-81. doi: 10.1111/j.0105-2896.2009.00874.x.
5
Presenting exogenous antigen to T cells.将外源性抗原呈递给T细胞。
Curr Protoc Immunol. 2010 Feb;Chapter 16:16.2.1-16.2.18. doi: 10.1002/0471142735.im1602s88.
6
Modulation of immune responses through direct activation of Toll-like receptors to T cells.通过直接激活 Toll 样受体对 T 细胞调节免疫应答。
Clin Exp Immunol. 2010 May;160(2):168-75. doi: 10.1111/j.1365-2249.2010.04091.x. Epub 2010 Jan 29.
7
Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses.吡非尼酮可抑制T细胞活化、增殖、细胞因子和趋化因子的产生以及宿主同种异体反应。
Transplantation. 2009 Aug 15;88(3):330-8. doi: 10.1097/TP.0b013e3181ae3392.
8
Isolation of dendritic cells.树突状细胞的分离
Curr Protoc Immunol. 2009 Aug;Chapter 3:3.7.1-3.7.19. doi: 10.1002/0471142735.im0307s86.
9
Blood monocyte subsets differentially give rise to CD103+ and CD103- pulmonary dendritic cell populations.血液单核细胞亚群以不同方式产生CD103 +和CD103 -肺树突状细胞群体。
J Immunol. 2008 Mar 1;180(5):3019-27. doi: 10.4049/jimmunol.180.5.3019.
10
Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection.1996年肺移植排斥反应诊断命名标准化工作方案的修订版。
J Heart Lung Transplant. 2007 Dec;26(12):1229-42. doi: 10.1016/j.healun.2007.10.017.